Global Long-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029
The global Long-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 1142.9 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).
Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
This report studies the global Long-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)
Global Long-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Long-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share
Global Long-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Long-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson and Kyowa Kirin, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Long-acting Recombinant Human Erythropoietin Drugs market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Long-acting Recombinant Human Erythropoietin Drugs Market, By Region:
1. How big is the global Long-acting Recombinant Human Erythropoietin Drugs market?
2. What is the demand of the global Long-acting Recombinant Human Erythropoietin Drugs market?
3. What is the year over year growth of the global Long-acting Recombinant Human Erythropoietin Drugs market?
4. What is the production and production value of the global Long-acting Recombinant Human Erythropoietin Drugs market?
5. Who are the key producers in the global Long-acting Recombinant Human Erythropoietin Drugs market?
Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
This report studies the global Long-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)
Global Long-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Long-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share
Global Long-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Long-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).
This reports profiles key players in the global Long-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson and Kyowa Kirin, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Long-acting Recombinant Human Erythropoietin Drugs market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Long-acting Recombinant Human Erythropoietin Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
- Anemia
- Kidney Disorders
- Others
- Amgen
- Johnson & Johnson
- Kyowa Kirin
1. How big is the global Long-acting Recombinant Human Erythropoietin Drugs market?
2. What is the demand of the global Long-acting Recombinant Human Erythropoietin Drugs market?
3. What is the year over year growth of the global Long-acting Recombinant Human Erythropoietin Drugs market?
4. What is the production and production value of the global Long-acting Recombinant Human Erythropoietin Drugs market?
5. Who are the key producers in the global Long-acting Recombinant Human Erythropoietin Drugs market?
1 SUPPLY SUMMARY
1.1 Long-acting Recombinant Human Erythropoietin Drugs Introduction
1.2 World Long-acting Recombinant Human Erythropoietin Drugs Supply & Forecast
1.2.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.2.3 World Long-acting Recombinant Human Erythropoietin Drugs Pricing Trends (2018-2029)
1.3 World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (Based on Production Site)
1.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2029)
1.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2029)
1.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
1.3.4 North America Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.5 Europe Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.6 China Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.7 Japan Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Long-acting Recombinant Human Erythropoietin Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Long-acting Recombinant Human Erythropoietin Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Long-acting Recombinant Human Erythropoietin Drugs Demand (2018-2029)
2.2 World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region
2.2.1 World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023)
2.2.2 World Long-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.4 China Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.5 Europe Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.6 Japan Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.7 South Korea Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.8 ASEAN Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.9 India Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
3 WORLD LONG-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023)
3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023)
3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
3.4 Long-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Long-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Long-acting Recombinant Human Erythropoietin Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Long-acting Recombinant Human Erythropoietin Drugs in 2022
3.6 Long-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
3.6.1 Long-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
3.6.2 Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
3.6.3 Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison
4.1.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Comparison
4.2.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison
4.3.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.5 China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share
4.5.1 China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.6 Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Long-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Epoetin-alfa
5.2.2 Epoetin-beta
5.2.3 Darbepoetin-alfa
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2029)
5.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2029)
5.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Long-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2029)
6.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2029)
6.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.1.4 Amgen Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.2.4 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Kyowa Kirin
7.3.1 Kyowa Kirin Details
7.3.2 Kyowa Kirin Major Business
7.3.3 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.3.4 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Kyowa Kirin Recent Developments/Updates
7.3.6 Kyowa Kirin Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Long-acting Recombinant Human Erythropoietin Drugs Industry Chain
8.2 Long-acting Recombinant Human Erythropoietin Drugs Upstream Analysis
8.2.1 Long-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.2.2 Main Manufacturers of Long-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Long-acting Recombinant Human Erythropoietin Drugs Production Mode
8.6 Long-acting Recombinant Human Erythropoietin Drugs Procurement Model
8.7 Long-acting Recombinant Human Erythropoietin Drugs Industry Sales Model and Sales Channels
8.7.1 Long-acting Recombinant Human Erythropoietin Drugs Sales Model
8.7.2 Long-acting Recombinant Human Erythropoietin Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Long-acting Recombinant Human Erythropoietin Drugs Introduction
1.2 World Long-acting Recombinant Human Erythropoietin Drugs Supply & Forecast
1.2.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018 & 2022 & 2029)
1.2.2 World Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.2.3 World Long-acting Recombinant Human Erythropoietin Drugs Pricing Trends (2018-2029)
1.3 World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (Based on Production Site)
1.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2029)
1.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2029)
1.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2029)
1.3.4 North America Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.5 Europe Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.6 China Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.3.7 Japan Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Long-acting Recombinant Human Erythropoietin Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Long-acting Recombinant Human Erythropoietin Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Long-acting Recombinant Human Erythropoietin Drugs Demand (2018-2029)
2.2 World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region
2.2.1 World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023)
2.2.2 World Long-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029)
2.3 United States Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.4 China Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.5 Europe Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.6 Japan Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.7 South Korea Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.8 ASEAN Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
2.9 India Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029)
3 WORLD LONG-ACTING RECOMBINANT HUMAN ERYTHROPOIETIN DRUGS MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023)
3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023)
3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023)
3.4 Long-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Long-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Long-acting Recombinant Human Erythropoietin Drugs in 2022
3.5.3 Global Concentration Ratios (CR8) for Long-acting Recombinant Human Erythropoietin Drugs in 2022
3.6 Long-acting Recombinant Human Erythropoietin Drugs Market: Overall Company Footprint Analysis
3.6.1 Long-acting Recombinant Human Erythropoietin Drugs Market: Region Footprint
3.6.2 Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
3.6.3 Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison
4.1.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Comparison
4.2.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison
4.3.1 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.4.3 United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.5 China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share
4.5.1 China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.5.3 China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
4.6 Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Long-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Epoetin-alfa
5.2.2 Epoetin-beta
5.2.3 Darbepoetin-alfa
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2029)
5.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2029)
5.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Long-acting Recombinant Human Erythropoietin Drugs Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Anemia
6.2.2 Kidney Disorders
6.2.3 Others
6.3 Market Segment by Application
6.3.1 World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2029)
6.3.2 World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2029)
6.3.3 World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.1.4 Amgen Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.2.4 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Kyowa Kirin
7.3.1 Kyowa Kirin Details
7.3.2 Kyowa Kirin Major Business
7.3.3 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Product and Services
7.3.4 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Kyowa Kirin Recent Developments/Updates
7.3.6 Kyowa Kirin Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Long-acting Recombinant Human Erythropoietin Drugs Industry Chain
8.2 Long-acting Recombinant Human Erythropoietin Drugs Upstream Analysis
8.2.1 Long-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.2.2 Main Manufacturers of Long-acting Recombinant Human Erythropoietin Drugs Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Long-acting Recombinant Human Erythropoietin Drugs Production Mode
8.6 Long-acting Recombinant Human Erythropoietin Drugs Procurement Model
8.7 Long-acting Recombinant Human Erythropoietin Drugs Industry Sales Model and Sales Channels
8.7.1 Long-acting Recombinant Human Erythropoietin Drugs Sales Model
8.7.2 Long-acting Recombinant Human Erythropoietin Drugs Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2023)
Table 9. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2024-2029)
Table 10. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Long-acting Recombinant Human Erythropoietin Drugs Major Market Trends
Table 13. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Long-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 18. World Long-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Long-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 20. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Long-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
Table 22. World Long-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Long-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
Table 24. Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
Table 25. Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
Table 26. Long-acting Recombinant Human Erythropoietin Drugs Competitive Factors
Table 27. Long-acting Recombinant Human Erythropoietin Drugs New Entrant and Capacity Expansion Plans
Table 28. Long-acting Recombinant Human Erythropoietin Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 37. China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 47. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 64. Amgen Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 68. Johnson & Johnson Major Business
Table 69. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 70. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Johnson & Johnson Recent Developments/Updates
Table 72. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 73. Kyowa Kirin Major Business
Table 74. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 75. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 76. Global Key Players of Long-acting Recombinant Human Erythropoietin Drugs Upstream (Raw Materials)
Table 77. Long-acting Recombinant Human Erythropoietin Drugs Typical Customers
Table 78. Long-acting Recombinant Human Erythropoietin Drugs Typical Distributors
LIST OF FIGURE
Figure 1. Long-acting Recombinant Human Erythropoietin Drugs Picture
Figure 2. World Long-acting Recombinant Human Erythropoietin Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Long-acting Recombinant Human Erythropoietin Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 5. World Long-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 10. China Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 12. Long-acting Recombinant Human Erythropoietin Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Long-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Long-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Long-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 26. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 32. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type in 2022
Figure 34. Epoetin-alfa
Figure 35. Epoetin-beta
Figure 36. Darbepoetin-alfa
Figure 37. Others
Figure 38. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Type (2018-2029)
Figure 39. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type (2018-2029)
Figure 40. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application in 2022
Figure 43. Anemia
Figure 44. Kidney Disorders
Figure 45. Others
Figure 46. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Application (2018-2029)
Figure 47. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application (2018-2029)
Figure 48. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Long-acting Recombinant Human Erythropoietin Drugs Industry Chain
Figure 50. Long-acting Recombinant Human Erythropoietin Drugs Procurement Model
Figure 51. Long-acting Recombinant Human Erythropoietin Drugs Sales Model
Figure 52. Long-acting Recombinant Human Erythropoietin Drugs Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
Table 1. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2018-2023) & (USD Million)
Table 3. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Region (2024-2029) & (USD Million)
Table 4. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2023)
Table 5. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2024-2029)
Table 6. World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2018-2023) & (K Units)
Table 7. World Long-acting Recombinant Human Erythropoietin Drugs Production by Region (2024-2029) & (K Units)
Table 8. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2023)
Table 9. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2024-2029)
Table 10. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Long-acting Recombinant Human Erythropoietin Drugs Major Market Trends
Table 13. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Long-acting Recombinant Human Erythropoietin Drugs Consumption by Region (2018-2023) & (K Units)
Table 15. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Long-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 18. World Long-acting Recombinant Human Erythropoietin Drugs Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Long-acting Recombinant Human Erythropoietin Drugs Producers in 2022
Table 20. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Long-acting Recombinant Human Erythropoietin Drugs Company Evaluation Quadrant
Table 22. World Long-acting Recombinant Human Erythropoietin Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Long-acting Recombinant Human Erythropoietin Drugs Production Site of Key Manufacturer
Table 24. Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Type Footprint
Table 25. Long-acting Recombinant Human Erythropoietin Drugs Market: Company Product Application Footprint
Table 26. Long-acting Recombinant Human Erythropoietin Drugs Competitive Factors
Table 27. Long-acting Recombinant Human Erythropoietin Drugs New Entrant and Capacity Expansion Plans
Table 28. Long-acting Recombinant Human Erythropoietin Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Long-acting Recombinant Human Erythropoietin Drugs Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 37. China Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 42. Rest of World Based Long-acting Recombinant Human Erythropoietin Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share (2018-2023)
Table 47. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2018-2023) & (K Units)
Table 49. World Long-acting Recombinant Human Erythropoietin Drugs Production by Type (2024-2029) & (K Units)
Table 50. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2018-2023) & (USD Million)
Table 51. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type (2024-2029) & (USD Million)
Table 52. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2018-2023) & (K Units)
Table 56. World Long-acting Recombinant Human Erythropoietin Drugs Production by Application (2024-2029) & (K Units)
Table 57. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2018-2023) & (USD Million)
Table 58. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application (2024-2029) & (USD Million)
Table 59. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 64. Amgen Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 68. Johnson & Johnson Major Business
Table 69. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 70. Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Johnson & Johnson Recent Developments/Updates
Table 72. Kyowa Kirin Basic Information, Manufacturing Base and Competitors
Table 73. Kyowa Kirin Major Business
Table 74. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Product and Services
Table 75. Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 76. Global Key Players of Long-acting Recombinant Human Erythropoietin Drugs Upstream (Raw Materials)
Table 77. Long-acting Recombinant Human Erythropoietin Drugs Typical Customers
Table 78. Long-acting Recombinant Human Erythropoietin Drugs Typical Distributors
LIST OF FIGURE
Figure 1. Long-acting Recombinant Human Erythropoietin Drugs Picture
Figure 2. World Long-acting Recombinant Human Erythropoietin Drugs Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Long-acting Recombinant Human Erythropoietin Drugs Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 5. World Long-acting Recombinant Human Erythropoietin Drugs Average Price (2018-2029) & (US$/Unit)
Figure 6. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Region (2018-2029)
Figure 7. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Region (2018-2029)
Figure 8. North America Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 9. Europe Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 10. China Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 11. Japan Long-acting Recombinant Human Erythropoietin Drugs Production (2018-2029) & (K Units)
Figure 12. Long-acting Recombinant Human Erythropoietin Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 15. World Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share by Region (2018-2029)
Figure 16. United States Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 17. China Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 18. Europe Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 19. Japan Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 20. South Korea Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 22. India Long-acting Recombinant Human Erythropoietin Drugs Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Long-acting Recombinant Human Erythropoietin Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Long-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Long-acting Recombinant Human Erythropoietin Drugs Markets in 2022
Figure 26. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Long-acting Recombinant Human Erythropoietin Drugs Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 30. China Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Production Market Share 2022
Figure 32. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type in 2022
Figure 34. Epoetin-alfa
Figure 35. Epoetin-beta
Figure 36. Darbepoetin-alfa
Figure 37. Others
Figure 38. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Type (2018-2029)
Figure 39. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Type (2018-2029)
Figure 40. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 41. World Long-acting Recombinant Human Erythropoietin Drugs Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 42. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application in 2022
Figure 43. Anemia
Figure 44. Kidney Disorders
Figure 45. Others
Figure 46. World Long-acting Recombinant Human Erythropoietin Drugs Production Market Share by Application (2018-2029)
Figure 47. World Long-acting Recombinant Human Erythropoietin Drugs Production Value Market Share by Application (2018-2029)
Figure 48. World Long-acting Recombinant Human Erythropoietin Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 49. Long-acting Recombinant Human Erythropoietin Drugs Industry Chain
Figure 50. Long-acting Recombinant Human Erythropoietin Drugs Procurement Model
Figure 51. Long-acting Recombinant Human Erythropoietin Drugs Sales Model
Figure 52. Long-acting Recombinant Human Erythropoietin Drugs Sales Channels, Direct Sales, and Distribution
Figure 53. Methodology
Figure 54. Research Process and Data Source
